FDA lifts OncoMed partial hold

Share this article:

The FDA lifted its partial clinical hold on OncoMed's anti-Fzd7 vantictumab last week. The drug was being tested among non-small cell lung cancer chemotherapy patients, as well as patients with advanced HER2-negative breast cancer or advanced pancreatic cancer. The FDA froze the clinical trial in July over concern about “bone-related adverse events.”

Jefferies analyst Thomas Wei wrote in a Thursday research note that OncoMed expects to modify dosing regimens and enrollment criteria.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.